IGF-1 LR3 vs MGF peptide
How IGF-1 LR3 and MGF peptide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
IGF-1 LR3 and MGF peptide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
IGF-1 LR3 vs MGF peptide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | IGF-1 LR3 | MGF peptide |
|---|---|---|
| What it is | Synthetic 83-amino-acid analogue of insulin-like growth factor 1 (IGF-1) | Synthetic 24-amino-acid peptide corresponding to the E-domain of the human IGF-1Ec splice variant |
| Class / category | GH secretagogues | GH secretagogues |
| Evidence tier | Animal-only · Unclear · none in humans | In-vitro · Mixed · none in humans |
| Studied / approved for | Muscle growth / anabolism (community use); Cell-culture / bioprocessing supplement (laboratory use) | Muscle repair and regeneration (cell research); Cardiac repair (animal research) |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 0 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | No human safety data exists for IGF-1 LR3 — every risk here is read off IGF-1 biology and animal work, not measured in people using it to build muscle. Hypoglycemia is the most predictable: IGF-1 lowers blood sugar (it's the headline warning on mecasermin, the approved native-IGF-1 drug), which is why cautious users keep fast-acting carbs on hand. Animal data adds organ and tissue overgrowth — infused Long R3 IGF-1 enlarged guinea-pig organs — and IGF-1's pro-growth, anti-cell-death signaling raises a real, unsettled cancer-promotion concern. And because most of what's sold is reagent-grade cell-culture material rather than a pharmaceutical, a vial's true identity and dose ride on a seller who never had to prove either. | MGF peptide has no established human safety profile, and FDA says it has found no human exposure data for drug products containing PEG-MGF by any route. The agency flags possible immune reactions, peptide-related impurities, and problems characterizing the active ingredient. Long-term risks, pharmacokinetics, and a safe human dose are unknown. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward IGF-1 LR3
IGF-1 LR3's evidence sits at animal-only, a more human tier than MGF peptide's in-vitro. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Voorhamme & Yandell, 2006 — LONG R3IGF-I as a more potent alternative to insulin in serum-free culture (PubMed)
- 2.Conlon et al., 1995 — Long R3 IGF-I infusion stimulates organ growth in the guinea pig (PubMed)
- 3.Bailes & Greetham, 2021 — IGF-1 and its monitoring in medical diagnostics and in sports (Biomolecules, PMC)
- 4.INCRELEX (mecasermin) FDA prescribing information — approved native rhIGF-1, for contrast
- 5.IGF-1 LR3 — indexed research (PubMed, National Library of Medicine)
- 6.IGF-1 LR3 — registered clinical studies (ClinicalTrials.gov)